ASCO: Overall Survival Up for African - American Men With mCRPC
Improved survival versus Caucasian men treated with docetaxel/prednisone, DP - containing regimen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 7, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news
ASCO: Overall Survival Up for African-American Men With mCRPC
THURSDAY, June 7, 2018 -- Overall survival is increased for African-American men with metastatic castration resistant prostate cancer (mCRPC) versus Caucasian men treated with docetaxel/prednisone (DP) or a DP-containing regimen, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 7, 2018 Category: Pharmaceuticals Source Type: news
Targeting chemotherapy with genetic testing benefits women with aggressive breast cancer
(Institute of Cancer Research) Women with an aggressive form of breast cancer who have faults in their BRCA genes do much better on chemotherapy drug carboplatin than standard treatment, a major clinical trial reports. Researchers found that women with advanced 'triple-negative' breast cancer who had inherited a BRCA mutation were twice as likely to benefit from carboplatin as docetaxel, which is currently standard of care for these patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2018 Category: Cancer & Oncology Source Type: news
Novel TKI Plus Chemo Dramatically Shrank Advanced Head & amp; Neck Tumors
AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial. (Source: CancerNetwork)
Source: CancerNetwork - April 25, 2018 Category: Cancer & Oncology Authors: Anne Landry Tags: Head & Neck Cancer Head and Neck Cancer Targets News Source Type: news
ASCO Issues New Metastatic Prostate Cancer Treatment Guide ASCO Issues New Metastatic Prostate Cancer Treatment Guide
Adding docetaxel or abiraterone to ADT improves metastatic prostate cancer survival, with patient and cost factors the most important considerations when choosing between them, say guidelines.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
MHSPC: Increased Survival with Added Docetaxel Confirmed Long-Term (CME/CE)
(MedPage Today) -- 13-month advantage in median overall survival (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 16, 2018 Category: Hematology Source Type: news
ASCO Supports New Options for Metastatic Prostate Cancer
(MedPage Today) -- Docetaxel, abiraterone plus ADT for non-CRPC (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 2, 2018 Category: Primary Care Source Type: news
Abiraterone, Docetaxel Best With ADT for Metastatic Prostate Cancer
Abiraterone plus prednisolone/prednisone, or docetaxel, combined with ADT may be the most effective therapies for metastatic hormone-naive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news
NanOlogy looks to transform chemotherapy with localized delivery platform
Paclitaxel revolutionized cancer treatment when it was first used as a chemotherapeutic in the 1990s. But although the product is a powerful cancer killer, patients taking systemic doses of paclitaxel have to endure side effects such as peripheral neuropathy and hair loss.
Marc Iacobucci and his team at NanOlogy believe they could replace the need for large, systemic doses of paclitaxel with the company’s unique formulation technique. NanOlogy has developed a way to turn drugs such as paclitaxel and docetaxel into sub-micron particles of pure drug that can be delivered locally to tumors.
Get the full story at our siste...
Source: Mass Device - March 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals nanology Source Type: news
Docetaxel for Prostate Cancer:'Win-Win-Win'Docetaxel for Prostate Cancer:'Win-Win-Win '
In both metastatic and nonmetastatic patients, the chemotherapy improved three important outcomes compared with previous standard of care.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Men with cancer live for 25% longer if given a drug early
British researchers showed men with the cancer live 25 per cent longer if given docetaxel – an established chemotherapy drug – early on in their treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - February 7, 2018 Category: Consumer Health News Source Type: news
Dr Reddy's recalls over 1,000 vials of cancer drug from US
Health regulators raised a red flag over a defect in the sealing of Docetaxel injection vials- a drug used for treating breast cancer. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 17, 2018 Category: Pharmaceuticals Source Type: news
NICE recommends VARGATEF ® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
VARGATEF ® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Adding Darolutamide Ups Survival in Metastatic Prostate Cancer
Risk for death lower with darolutamide versus placebo, combined with androgen - deprivation therapy and docetaxel (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news
